The control of allergic rhinitis in real life: A multicenter cross-sectional Italian study

被引：17

作者：

Gani F. ^{[1
]}

Lombardi C. ^{[2
]}

Barrocu L. ^{[1
]}

Landi M. ^{[3
]}

Ridolo E. ^{[4
]}

Bugiani M. ^{[5
]}

Rolla G. ^{[6
]}

Senna G. ^{[7
]}

Passalacqua G. ^{[8
]}

机构：

[1] Azienda Ospedaliera San Luigi Orbassano, Allergy Service, Turin

[2] Fondazione Poliambulanza, Departmental Unit of Allergology and Respiratory Diseases, Brescia

[3] National Healthcare System, Primary Care Pediatrician, Turin

[4] University of Parma, Experimental and Clinical Medicine, Parma

[5] Consultant Physician of Professional Diseases Observatory, Procura della Repubblica, Turin

[6] University of Turin, AO Mauriziano, Allergology and Immunology, Turin

[7] Verona University and General Hospital, Asthma Center and Allergy Unit, Verona

[8] IRCCS San Martino-IST University of Genoa, Allergy and Respiratory Diseases, Genoa

来源：

Clinical and Molecular Allergy | / 16卷 / 1期

关键词：

Allergic rhinitis; Control; Real-life;

D O I：

10.1186/s12948-018-0082-y

中图分类号：

学科分类号：

摘要：

Background: Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general population is affected, and in Italy the prevalence is estimated to be 19.8%. The Allergic Rhinitis and its Impact on Asthma (ARIA) international document underlined that the prevalence of severe or refractory or overlapping rhinitis is increasing and represents a non-negligible socio-economic burden. In general, despite the social healthcare costs, allergic rhinitis remains underestimated, not sufficiently controlled and often undertreated. Aim of the study: In this multi-center Italian observational and prospective study we assessed the control of AR in patients (>16years) without previous asthma diagnosis, referred to Allergy Centers. Methods: Patients of both sexes and older than 16 with rhinitis symptoms and without asthma were studied. A Visual Analogue Scale (VAS) and the CARAT (Control of Allergic Rhinitis and Asthma Test) were used as patient reported outcome. The possible causes of poor control of AR, as per protocol, were assessed accordingly. Results: We observed 250 patients in a real-life setting: more than 60% of them had an uncontrolled AR, only about 50% used multiple medications, and only a minority were receiving allergen immunotherapy. Conclusion: This survey, conducted in a real-life setting, confirmed that AR is overall poorly controlled. The VAS assessment well correlates with the structured CARAT questionnaire and with the relevant symptoms of AR. © 2018 The Author(s).

引用

共 26 条

[1]

Bauchau V., Durham S.R., Prevalence and rate of diagnosis of allergic rhinitis in Europe, Eur Respir J, 24, 5, pp. 758-764, (2004)

[2]

Bousquet J., Schunemann H.J., Zuberbier T., Bachert C., Baena-Cagnani C.E., Bousquet P.J., Brozek J., Canonica G.W., Et al., Development and implementation of guidelines in allergic rhinitis-an ARIA-GA2LEN paper, Allergy, 65, 10, pp. 1212-1221, (2010)

[3]

Bousquet J., Hellings P.W., Agache I., Bedbrook A., Bachert C., Bergmann K.C., Bewick M., Bindslev-Jensen C., Et al., ARIA 2016: Care pathway implementing emerging technologies predictive medicine in rhinitis and asthma across the life cicle, Clin Transl Allergy, 30, 6, (2016)

[4]

Bousquet J., Anto J.M., Demoly P., Schunemann H.J., Togias A., Akdis M., Et al., Severe chronic allergic (and related) diseases: a uniform approach-a MeDALL-GA2LEN-ARIA position paper, Int Arch Allergy Immunol, 158, 3, pp. 216-231, (2012)

[5]

Canonica G.W., Triggiani M., Senna G., 360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients, Clin Molec All, 2, pp. 13-25, (2015)

[6]

Passalacqua G., Bousquet P.J., Carlsen K.H., Kemp J., Lockey R.F., Niggemann B., Et al., ARIA update: systematic review of complementary and alternative medicine for rhinitis and asthma, J Allergy Clin Immunol., 117, 5, pp. 1054-1062, (2006)

[7]

Canonica G.W., Baena-Cagnani C.E., Compalati E., Bohle B., Bonini S., Bousquet J., Et al., 100years of immunotherapy: the monaco charter, Int Arch Allergy Immunol, 160, pp. 346-349, (2013)

[8]

Belhassen M., Demoly P., Bloch-Morot E., de Pouvourville G., Ginoux M., Chartier A., Laforest L., Serup-Hansen N., Toussi M., Van Ganse E., Costs of perennial allergic rhinitis and allergic asthma increase with severity and poor disease control, Allergy., (2016)

[9]

Passalacqua G., Canonica G.W., AIT (allergen immunotherapy): a model for the "precision medicine, Clin Mol Allergy., 8, 13, (2015)

[10]

Wheatley L.M., Togias A., Clinical practice, allergic rhinitis, N Engl J Med., 372, 5, pp. 456-463, (2015)

← 1 2 3 →